On February 2, 2021, Engrail Therapeutics announced that it has acquired NeuroCycle Therapeutics, a company focused on sub-type selective GABA-A modulation. The acquisition strengthens Engrail’s presence in the GABA-A space and provides a strong platform for initiation of clinical trials with multiple assets in 2021. Wilson Sonsini Goodrich & Rosati represented NeuroCycle Therapeutics in the transaction.

NeuroCycle Therapeutics CEO and president Jed Hubbs, Ph.D., said, “We believe Engrail represents the ideal company to carry on the work NeuroCycle started given their focus and experience in the GABA-A space. We look forward to seeing them bring novel medicines to patients that need them.”

The Wilson Sonsini team that represented NeuroCycle Therapeutics in the transaction includes:

Corporate
Mark Solakian, Partner
Elisa Sielski, Associate
Leah Hengemuhle, Associate

Technology Transactions
Farah Gerdes, Partner

Patents and Innovations
Louis Lieto, Partner

Tax
Gregory Broome, Partner

For more information, please see Engrail's press release.